PRINCETON, N.J.--(BUSINESS WIRE)--PhytoMedical Technologies, Inc. (OTCBB:PYTO) (FWB:ET6), today announced preliminary results from recent low-dosage animal studies of the Company’s compounds for type-2 diabetes. The compounds being tested are synthetic versions of the isolated active metabolite derived from cinnamon and potentially represent an entirely new class of compounds for the treatment of type-2 diabetes.
